Increase biotherapeutic potency and efficacy with CHOSOURCE™ ADDC+ cell line
CHOSOURCE ADCC+ cell line eliminates the cell’s natural fucosylation activity to increase therapeutic protein efficacy and potency. Elimination of core fucose on the glycan of the Fc-region of antibodies enhances antibody-dependent cellular cytotoxicity (ADCC) activity of immune effector cells by increasing antibody binding to the CD16a receptor present on effector cells.
This cell line is a double knockout in both the glutamine synthetase (GS) and fucosyltransferase genes. This unique modification enables the production of afucosylated proteins within a traditional GS background.
Producing afucosylated antibodies offers various advantages, including a significant increase in the therapeutic efficacy and potency of antibodies, as well as reducing batch-to-batch variation with regards to product fucosylation. This enhancement often results in reduced dosage requirements, potentially alleviating undesired side effects.
